Passage Bio Inc
Focused on developing therapies for rare, monogenic central nervous system (CNS) disorders
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Passage Bio's stock with a target price of $7, indicating significant growth potential.
Financial Health
Passage Bio Inc shows strong cash flow and a solid book value per share, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PASG
Beyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage catalyst watch
Clinical readouts and regulatory milestones can create sharp share-price moves, though outcomes are binary and performance can vary.
Rare disease focus
Concentrating on rare monogenic neurological disorders can mean high scientific value if successful, but small patient populations and regulatory hurdles add uncertainty.
High scientific risk
Gene therapy development is technically complex and capital-intensive; investors should expect dilution risk and long timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
